-transparent.png){kind=logo}
[Fosfomycin for treatment of uncomplicated lower urinary tract infection]. 2018
Department of urology Federal State Budgetary Educational Institution of Higher Education Academician I.P. Pavlov First St. Petersburg State Medical University, Saint Petersburg, Russia.
In this article the current data on using of antibacterial drug Fosfomycin for treatment of lower urinary tract infection are reviewed. The distinct features of pharmacodynamics and pharmacokinetics of fosfomycin, as well as the spectrum of its antimicrobial activity are thoroughly discussed. The current information on the resistance of uropathogens, including those that produce extended-spectrum -lactamase, are presented.
Related Publications
S H Al-Shukri, and
M N Slesarevskaya, and
I V Kuzmin
January 2016,
BMJ (Clinical research ed.),
S H Al-Shukri, and
M N Slesarevskaya, and
I V Kuzmin
March 2023,
Biomedicines,
S H Al-Shukri, and
M N Slesarevskaya, and
I V Kuzmin
January 2018,
Urology annals,
S H Al-Shukri, and
M N Slesarevskaya, and
I V Kuzmin
January 1992,
Infection,
S H Al-Shukri, and
M N Slesarevskaya, and
I V Kuzmin
December 2005,
Enfermedades infecciosas y microbiologia clinica,
S H Al-Shukri, and
M N Slesarevskaya, and
I V Kuzmin
December 2015,
BMJ (Clinical research ed.),
S H Al-Shukri, and
M N Slesarevskaya, and
I V Kuzmin
January 1990,
Chemotherapy,
S H Al-Shukri, and
M N Slesarevskaya, and
I V Kuzmin
January 2011,
Aktuelle Urologie,
S H Al-Shukri, and
M N Slesarevskaya, and
I V Kuzmin
January 2021,
PloS one,
S H Al-Shukri, and
M N Slesarevskaya, and
I V Kuzmin
January 1975,
Chemotherapy,
